 Ocugen Inc NASDAQ: OCGN announced the publication of positive pediatric Phase 23 study results in children aged 218 years for COVID-19 vaccine, Covaxin BBV152, in The Lancet Infectious Diseases. Covaxin is developed and manufactured by Ocugens India-based partner. 